ArticleFrontiers in genetics2026
Clinical and genomic characterization of corpus callosum abnormalities (CCA) in 107 Tunisian patients using a stepwise diagnostic approach.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Corpus callosum abnormalities (CCA) represent a heterogeneous group of neurodevelopmental disorders resulting from disturbances in midline patterning, neuronal migration, and axonal guidance. Their genetic architecture includes chromosomal abnormalities, pathogenic copy-number variations (CNVs), and single-gene disorders; however, genotype-phenotype correlations remain incompletely defined, particularly in underrepresented populations. Methods: We investigated the clinical and genomic characteristics of 107 Tunisian patients with radiologically confirmed CCA recruited over a 15-year period. A sequential genomic strategy was applied, including conventional karyotyping in all patients, fluorescence Results: Most patients presented syndromic forms of CCA (95.3%) associated with additional cerebral and/or extracerebral manifestations. Clinically relevant genomic abnormalities supporting a molecular diagnosis were identified in 11/107 patients (10.3%). Conventional karyotyping identified chromosomal abnormalities in three patients (2.8%), while array-CGH detected pathogenic or likely pathogenic CNVs in ten of 54 tested patients (18.5%). These CNVs involved genomic regions previously implicated in neurodevelopmental disorders and CCA, including 14q12, 4p16.3-p16.1, 1q43-q44, 1p32.3p31.3 -p32, 5p14.3, 5q35, 16q23.1-q24.3, and 18pterp11.1. WES identified rare variants in Conclusion: This study provides a comprehensive characterization of CCA in a Tunisian referral cohort and highlights the major contribution of pathogenic genomic imbalances to the molecular diagnosis of these disorders. The findings emphasize the complementary role of cytogenetic and sequencing approaches while illustrating the challenges of interpreting rare sequence variants in patients with complex neurodevelopmental phenotypes. Larger cohorts with systzbematic genomic testing, segregation analyses, and functional validation will be required to further refine genotype-phenotype correlations in CCA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.